Stockscreener 앱 받기
13.36
0.82%
-0.13
전일 마감가:
$13.49
열려 있는:
$13.5
하루 거래량:
260.68K
Relative Volume:
0.18
시가총액:
$733.50M
수익:
$15.84M
순이익/손실:
$-308.48M
주가수익비율:
-2.0617
EPS:
-6.48
순현금흐름:
$-153.08M
1주 성능:
-3.88%
1개월 성능:
-6.50%
6개월 성능:
-8.54%
1년 성능:
+87.92%
1일 변동 폭
$13.26
$13.73
1주일 범위
$13.26
$14.43
52주 변동 폭
$4.45
$19.18
Uniqure N V Stock (QURE) Company Profile
명칭
Uniqure N V
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
QURE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
13.37 | 768.14M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.63 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.35 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.99 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
668.90 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.87 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure N V 주식(QURE)의 최신 뉴스
Aberdeen Group plc Expands Stake in uniQure NV with Strategic Ac - GuruFocus
Is uniQure N.V. a good long term investmentGet exclusive access to premium stock research - Jammu Links News
What is uniQure N.V. company’s growth strategyStrongest growth potential - Jammu Links News
Should I hold or sell uniQure N.V. stock in 2025Unlock daily market insights for better trades - Jammu Links News
What makes uniQure N.V. stock price move sharplyBuild a strong portfolio for long-term success - Jammu Links News
What drives uniQure N.V. stock priceUnprecedented market success - Jammu Links News
Is uniQure N.V. a growth stock or a value stockMaximize returns with disciplined investment techniques - Jammu Links News
What is the risk reward ratio of investing in uniQure N.V. stockOutstanding growth strategies - Jammu Links News
What are the latest earnings results for uniQure N.V.Discover undervalued stocks before they soar - Jammu Links News
How does uniQure N.V. compare to its industry peersMaximize your gains with expert trading tips - Jammu Links News
Is uniQure N.V. stock overvalued or undervaluedDiscover high-impact stocks for your portfolio - Jammu Links News
What analysts say about uniQure N.V. stockDiscover breakthrough stocks before the crowd - Jammu Links News
How strong is uniQure N.V. company’s balance sheetBuild wealth faster with professional insights - Jammu Links News
What are the technical indicators suggesting about uniQure N.V.High-octane gains - Jammu Links News
Why is uniQure N.V. stock attracting strong analyst attentionEntry Signal Signals To Watch Now - Jammu Links News
UniQure N.V. (NASDAQ:QURE) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $35 to $35 - 富途牛牛
uniQure Reports Q2 2025 Progress and Financials - TipRanks
uniQure’s AMT-130 Gene Therapy for Huntington’s Disease on Track for Q1 2026 BLA Submission After FDA Alignment - Insider Monkey
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Yahoo Finance
uniQure N.V. (NASDAQ:QURE) Q2 2025 Earnings Call Transcript - Insider Monkey
uniQure N.V. Earnings Call: Progress Amid Challenges - TipRanks
Chardan Capital Analyst Downgrades uniQure Price Target to $35.00, Maintains Buy Rating - AInvest
What Caused uniQure’s (QURE.O) Sudden Intraday Surge? - AInvest
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
UniQure outlines planned BLA submission for AMT-130 in Q1 2026 amid regulatory alignment and pipeline momentum - MSN
UniQure shares rise 9.65% premarket after FDA alignment on AMT-130 statistical analysis plan and CMC requirements. - AInvest
UniQure: Q2 Earnings Snapshot - Huron Daily Tribune
UniQure shares rise 12.35% premarket after FDA alignment on AMT-130 and positive clinical data. - AInvest
uniQure NV (QURE) Q2 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... By GuruFocus - Investing.com Canada
Chardan Capital maintains Buy rating for uniQure with $35 PT. - AInvest
uniQure shares tumble as Q2 revenue misses expectations By Investing.com - Investing.com Canada
uniQure shares tumble as Q2 revenue misses expectations - Investing.com
uniQure Announces $200 Million Sales Agreement - TipRanks
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Uniqure NV earnings beat by $0.20, revenue fell short of estimates - Investing.com Nigeria
uniQure N.V. SEC 10-Q Report - TradingView
Uniqure N V (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Uniqure N V 주식 (QURE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Springhorn Jeremy P. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,694 |
| POST LEONARD E | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
29,937 |
| Kaye Jack | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
20,439 |
| Jacques Rachelle Suzanne | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
28,346 |
| Gut Robert | Director |
Jun 20 '25 |
Sale |
14.45 |
3,336 |
48,205 |
56,879 |
| Balachandran Madhavan | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,697 |
| Meek David D. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
34,190 |
| Potts Jeannette | Chief Legal Officer |
Jun 16 '25 |
Sale |
15.14 |
4,670 |
70,704 |
115,073 |
| Kapusta Matthew C | CEO, Managing Director |
Mar 04 '25 |
Sale |
10.29 |
28,341 |
291,629 |
651,454 |
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
0.28%
2.25%
자본화:
|
볼륨(24시간):